Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6364

Provisional Schedule

Committee meeting: 1 03 October 2024
Expected publication 11 December 2024

Project Team

Project lead Kate Moore

Email enquiries

External Assessment Group Southampton Health Technology Assessment Centre (SHTAC), University of Southampton


Companies sponsors Amgen (tarlatamab)
Others Department of Health and Social Care
  NHS England
Patient carer groups Roy Castle Lung Cancer Foundation
Professional groups Association of Cancer Physicians
  British Thoracic Oncology Group
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
Comparator companies Accord Healthcare - not participating
  Baxter Healthcare - not participating
  CNX therapeutics - not participating
  Fresenius Kabi - not participating
  Hospira UK - not participating
  Medac GmbH - not participating
  Neon Healthcare - not participating
  Novartis (topotecan)
  Pfizer - not participating
  Sandoz - not participating
  Seacross Pharmaceuticals - not participating
  Servier - not participating
  Sun pharma - not participating
  Teva UK - not participating
  Zentiva - not participating
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health - Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research


Key events during the development of the guidance:

Date Update
05 March 2024 Invitation to participate
22 January 2024 - 05 February 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6364
22 January 2024 In progress. Scoping commenced.
22 September 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual